Rivaroxaban: A New Oral Factor Xa Inhibitor
نویسندگان
چکیده
منابع مشابه
DVT: A New Era in Anticoagulant Therapy Rivaroxaban: A New Oral Factor Xa Inhibitor
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has 10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC50], 20 mol/L). Rivaroxaban inhibits fa...
متن کاملDVT: A New Era in Anticoagulation Therapy Rivaroxaban: A New Oral Factor Xa Inhibitor
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has 10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC50], 20 mol/L). Rivaroxaban inhibits fa...
متن کاملRivaroxaban: an oral direct inhibitor of factor Xa.
PURPOSE The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban are reviewed. SUMMARY Rivaroxaban, the first oral, direct factor Xa (FXa) inhibitor to reach Phase III trials, inhibits thrombin generation by both the intrinsic and the tissue factor pathways. It has shown predictabl...
متن کاملRivaroxaban , a new oral factor Xa inhibitor , provides new data on anticoagulation
“Given the limitations with the vitamin K antagonists, there has been an ever-increasing need for the development of new an coagulant therapies.” Aurangzeb Siddique Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK Gregory YH Lip Haemostasis, Thrombosis & Vascular Biology Unit, University Department of Medicine, City Hospital, Birm...
متن کاملA New Oral Direct Factor Xa Inhibitor
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arteriosclerosis, Thrombosis, and Vascular Biology
سال: 2010
ISSN: 1079-5642,1524-4636
DOI: 10.1161/atvbaha.110.202978